Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

Exclusion Criteria

• •Mentally/legally incapacitated, or significant emotional problems or significant psychiatric disorder
• •History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, respiratory, genitourinary or major neurological abnormalities or diseases
• •History of any illness that might confound the results of the study or poses an additional risk to the participant by their participation in the study
• •Clinically significant history of cancer
• •Smoker and/or has used nicotine or nicotine-containing products within 3 months prior to screening
• •Female participants of childbearing potential, pregnant, or lactating
• •Positive results for urine or saliva drug screen and/or urine or breath alcohol screen at screening or check-in
• •Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
• •Consumes more than 3 glasses of alcoholic beverages within 6 months of screening
• •Consumes excessive amounts of coffee, tea, cola, energy-drinks, or other caffeinated beverages per day
• •Major surgery, donated or lost 1 unit of blood within 4 weeks prior to screening, or donated plasma within 7 days prior to dosing in Part 1 or first dose in Part 2
• •Renal Impaired Participants
• •Panels A, B, and C: Failed renal transplant or has had nephrectomy
• •Panels A, B, and C: Rapidly fluctuating renal function, as determined by historical measurements; or demonstrated/suspected renal artery stenosis
• •Panel E only: Has required frequent emergent HD (≥3) within a year prior to first dosing
• •Healthy Participants
• •Renal transplant or nephrectomy